# Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

> **NCT04716933** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 201 (actual)

## Conditions studied

- Nonsquamous Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Lenvatinib
- **DRUG:** Placebo matching lenvatinib

## Key facts

- **NCT ID:** NCT04716933
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-05
- **Primary completion:** 2023-08-11
- **Final completion:** 2024-08-30
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04716933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04716933, "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04716933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*